Esssex and Henlius Signed Amendment Agreement for Global Co-Development and Exclusive License Agreement for the Treatment of Age-related Macular Degeneration
Essex Bio-Investment and Henlius will co-develop the bevacizumab HLX04 (the "Product" or "EB12-20145P") for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD). Essex Bio-Investment has an exclusive global license to develop, manufacture, and commercialise the Product in the field of human ophthalmic therapeutic use and/or therapies.